TY - JOUR
T1 - Transformations of marginal zone lymphomas and lymphoplasmacytic lymphomas Report from the 2021 SH/eAHP workshop
AU - Cook, James R.
AU - Amador, Catalina
AU - Czader, Magdalena
AU - Duffield, Amy
AU - Goodlad, John
AU - Ott, German
AU - Xiao, Wenbin
AU - Dave, Sandeep
AU - Thakkar, Devang
AU - Thacker, Elizabeth
AU - Dogan, Ahmet
AU - Wasik, Mariusz
AU - Nejati, Reza
N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2023/6/1
Y1 - 2023/6/1
N2 - Objectives: To summarize the conclusions of the 2021 Society for Hematopathology/ European Association for Haematopathology workshop regarding transformations of marginal zone lymphoma (MZL) and lymphoplasmacytic lymphoma (LPL). Methods: Nineteen cases were submitted to this portion of the workshop. Additional studies were performed in cases with sufficient material. Results: Cases included splenic MZL (n = 4), splenic diffuse red pulp small B-cell lymphoma (n = 2), nodal MZL (n = 4), extranodal MZL (n = 1), and LPL (n = 8). The most common transformation was to diffuse large B-cell lymphoma (DLBCL), but others included classic Hodgkin lymphoma, high-grade B-cell lymphomas with MYC and BCL6 rearrangements, plasmablastic lymphoma, and plasma cell leukemia. Two splenic MZLs with transformation to DLBCL contained t(14;19)(q32;q13.3) IGH::BCL3 rearrangements in both samples. Paired sequencing studies in 5 MZLs with transformation to clonally related DLBCL identified a variety of mutations and gene fusions at the time of transformation, including CARD11, IGH::MYC, NOTCH2, P2RY8, TBLX1X1, and IGH::CD274. Conclusions: Marginal zone lymphoma and LPL may undergo a variety of transformation events, most commonly to DLBCL, which is usually, although not always, directly clonally related to the underlying low-grade lymphoma. Multiparameter analysis including broad-based sequencing studies can assist in the diagnosis and classification of these uncommon cases.
AB - Objectives: To summarize the conclusions of the 2021 Society for Hematopathology/ European Association for Haematopathology workshop regarding transformations of marginal zone lymphoma (MZL) and lymphoplasmacytic lymphoma (LPL). Methods: Nineteen cases were submitted to this portion of the workshop. Additional studies were performed in cases with sufficient material. Results: Cases included splenic MZL (n = 4), splenic diffuse red pulp small B-cell lymphoma (n = 2), nodal MZL (n = 4), extranodal MZL (n = 1), and LPL (n = 8). The most common transformation was to diffuse large B-cell lymphoma (DLBCL), but others included classic Hodgkin lymphoma, high-grade B-cell lymphomas with MYC and BCL6 rearrangements, plasmablastic lymphoma, and plasma cell leukemia. Two splenic MZLs with transformation to DLBCL contained t(14;19)(q32;q13.3) IGH::BCL3 rearrangements in both samples. Paired sequencing studies in 5 MZLs with transformation to clonally related DLBCL identified a variety of mutations and gene fusions at the time of transformation, including CARD11, IGH::MYC, NOTCH2, P2RY8, TBLX1X1, and IGH::CD274. Conclusions: Marginal zone lymphoma and LPL may undergo a variety of transformation events, most commonly to DLBCL, which is usually, although not always, directly clonally related to the underlying low-grade lymphoma. Multiparameter analysis including broad-based sequencing studies can assist in the diagnosis and classification of these uncommon cases.
KW - Lymphoplasmacytic lymphoma
KW - Marginal zone lymphoma
KW - Transdifferentiation
KW - Transformation
UR - http://www.scopus.com/inward/record.url?scp=85162080862&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000976722300001&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1093/ajcp/aqad034
DO - 10.1093/ajcp/aqad034
M3 - Article
C2 - 37186259
SN - 0002-9173
VL - 159
SP - 614
EP - 625
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
IS - 6
ER -